Cell therapy has the potential to become a feasible solution
for
several diseases, such as those related to the lungs and airways,
considering the more beneficial intratracheal administration route.
However, in lung diseases, an impaired pulmonary extracellular matrix
(ECM) precludes injury resolution with a faulty engraftment of mesenchymal
stem cells (MSCs) at the lung level. Furthermore, a shielding strategy
to avoid cell damage as well as cell loss due to backflow through
the injection path is required. Here, an approach to deliver cells
encapsulated in a biomimetic stem niche is used, in which the interplay
between cells and physiological lung ECM constituents, such as collagen
and hyaluronic acid (HA), can occur. To this aim, a biphasic delivery
system based on MSCs encapsulated in collagen microspheres (mCOLLs)
without chemical modification and embedded in an injectable HA solution
has been developed. Such biphasic delivery systems can both increase
the mucoadhesive properties at the site of interest and improve cell
viability and pulmonary differentiation. Rheological results showed
a similar viscosity at high shear rates compared to the MSC suspension
used in intratracheal administration. The size of the mCOLLs can
be controlled, resulting in a lower value of 200 μm, suitable
for delivery in alveolar sacs. Biological results showed that mCOLLs
maintained good cell viability, and when they were suspended in lung
medium implemented with low molecular weight HA, the differentiation
ability of the MSCs was further enhanced compared to their differentiation
ability in only lung medium. Overall, the results showed that this
strategy has the potential to improve the delivery and viability of
MSCs, along with their differentiation ability, in the pulmonary lineage.